Hikma continues buying spree with stake in China's Hubei Haosun
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals of Jordan continues to strengthen its Asian presence, this time through the acquisition of a 'significant' minority interest in the privately-owned Chinese actives maker, Hubei Haosun Pharmaceutical.